Case report

Treatment of bilateral ovarian dysgerminoma with 11-year follow-up: A case report

Luciano Zogbi, Carla Vitola Gonçalves, Victor Felipe Tejada, Daiane Martins, Fabine Karam, Sílvia Machado dos Santos, Roberta Raseira Caldeira, Gisele Zanetti Senhorin, Susi Lauz

Faculdade de Medicina (FAMED) – Universidade Federal do Rio Grande (FURG), Rio Grande city, Rio Grande do Sul State, Brazil

Abstract

Introduction: Malignant ovarian germ cell tumors (MOGCTs) are rare malignancies with an incidence of about 0.5/100,000. They account for less than 5% of all ovarian tumors, of which 32.8% are dysgerminomas, the female analogue of seminomas. These tumors occur in all age groups, with peak incidence below the age of 20 years in women.

Aim: To describe the case of a bilateral ovarian dysgerminoma treatment with 11-year follow-up.

Methods: Case report with details regarding clinical history, surgical treatment, chemotherapy and follow up. We include a brief literature review.

Results: The patient underwent radical surgery for an advanced dysgerminoma, 20 cm in length, that compromised the contralateral ovary and sigmoid. Neoplastic cells were found in ascitic fluid. Subsequently, she underwent adjuvant chemotherapy according to a standard protocol. She has survived disease-free for more than 11 years.

Conclusions: Dysgerminoma is a malignant neoplasm that, similar to other cancers, is easier to treat when diagnosed early. However, cures may be obtained even in advanced cases.

1. Introduction

Malignant ovarian germ cell tumors (MOGCTs) are rare malignancies with an incidence of about 0.5/100,000. They account for less than 5% of all ovarian tumors, of which 32.8% are dysgerminomas, the female analogue of seminomas. These tumors occur in all age groups, with peak incidence below the age of 20 years in women [1–5]. The aim of the manuscript was to report on a case of 16-year-old female who underwent radical surgery and chemotherapy for an advanced dysgerminoma. The work has been reported in line with the SCARE criteria [6].

2. Case report

2.1. Clinical history

A 16-year-old single female Caucasian presented with painless increase in abdominal volume of 1 month's duration. This was associated with fever and weight loss of 10 kg over 2 months. Past medical history was notable for menarche at age 12. She denied smoking, alcoholism, and drug use.

The physical examination revealed a palpable, indurated, painless mass in the lower portion of the abdomen, more than 15 cm in length. Imaging revealed a solid, heterogeneous ovarian mass, with well-defined limits, measuring $148 \times 135 \times 101$ mm, volume $1067 \text{ cm}^3$, with high-speed arterial flow and low resistance in internal vessels. Estimated weight was $1500$ g. Serum Cancer Antigen 125 (CA-125) level was $193$ U/mL. There were no abnormalities in other laboratory tests and no evidence of distant metastases.

2.2. Treatment

The tumor mass was resected within the left ovary. Pathological analysis revealed a tumor of $200 \times 160 \times 120$ mm, weighing $1627$ g. Pathology revealed a dysgerminoma with focal extension to the outer capsular surface, and presence of neoplastic cells in the ascitic fluid. She underwent cytoreductive surgery. We noted adhesions with surrounding viscera. Therefore, we performed right oophorectomy, total...
hysterectomy, lymphadenectomy, omentectomy, and sigmoidectomy en bloc with the lesion. We then performed end-to-end anastomosis (Fig. 1). After cytoreductive surgery, pathology revealed that there was chronic cervicitis with squamous metaplasia in the uterine cervix, lymph nodes with reactive lymphoid hyperplasia without neoplasia, and dysgerminoma in the remaining ovary with subcapsular space impairment, without capsule infiltration.

Her postoperative course was unremarkable for the first three days. Subsequently, she experienced abdominal pain, fever, and fecal discharge from the incision. We diagnosed a low output colonic fistula. We managed this with antibiotic therapy and oral nutritional support. There was complete closure of the fistula in approximately 1 month. She underwent adjuvant chemotherapy with bleomycin, etoposide, and cisplatin for 3 cycles.

2.3. Follow up

At outpatient follow-up, she had no evidence of relapse, with normalization of weight, development, and laboratory parameters. She underwent hormonal replacement and has been well for 11 years. An interesting fact was that the patient discovered her aptitude for medicine, and directed her studies to nursing. She works in the same hospital where she underwent surgery and is now describing her own case together with the treatment team.

3. Discussion

The ovary can host the most diverse and rare types of neoplasms. In addition, it can reach large dimensions until the first symptoms appear [7–11]. This report describes a case of an unusual disease, treated radically with optimal survival and effective cure, which is important to enrich the current literature about rare ovarian neoplasms. There was also an unusual outcome in her private life.

For MOGCTs in young patients, it is recommended that surgery be as conservative as possible. The majority (75%) of the patients are diagnosed as FIGO stage I. The 5-year survival of the affected patients is 95%. However, this patient was in stage IIIC (T2C, N0, M0) according to The American Joint Committee on Cancer (AJCC) TNM classification and the International Federation of Gynecology and Obstetrics (FIGO) staging system for germ cell tumors. Omentectomy and hysterectomy can usually be avoided in early cases of MOGCT [1–5]. However, we opted for radical cytoreductive surgery, because of this tumor’s bilaterality, large dimensions, the presence of neoplastic cells in the peritoneal fluid, and the extracapsular invasion of the tumor with invasion of the colon. We performed lymphadenectomy, hysterectomy, partial colectomy, and omentectomy.

The presence of residual tumor after surgery appears to be the single most important poor prognostic factor. In Li’s study of 34 patients who underwent salvage cytoreductive surgery, 5-year survival was 61% in the optimally cytoreduced group (≤1 cm), compared with 14% in the suboptimally cytoreduced group [12]. Meisel found recurrence in 31% patients [4], despite good results with more conservative surgery.

Our patient’s case fell within the limits of the Solheim classification: of 815 ovarian dysgerminoma patients, 93% were less than 40 years old, 69% were single, and 69% had educational class 2 (intermediate) or 3 (highest). Although there was a reasonable survival rate, they found that the risk of death from ovarian cancer was 9-fold greater in dysgerminoma patients [13]. Bilaterality is rare in MOGCTs, with a reported prevalence of 4.3%–6.9%. The rate increases to 10%–15% for dysgerminomas [14].

Adjuvant chemotherapy is the only independent prognostic factor for longer disease-free survival, and is considered essential for all patients, apart from those with stage IA disease [3]. Adjuvant chemotherapy with bleomycin, etoposide, and cisplatin is considered standard, even for advanced stage disease [15].

In spite of radical surgery, the patient overcame all her obstacles: not only with respect to disease itself, but also in her personal and professional life.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Ethics approval and consent to participate

The study was approved by the Institution’s Ethics Committee and written informed consent was obtained from the patient for publication of this case report and accompanying images.

Funding

The referred patient was attended in a public hospital where the authors work and the study did not receive any financial contribution.

Conflicts of interest

All the authors report no financial interests or potential conflicts of interest.

Registration of research studies

Not applicable.

Guarantor

Luciano Zogbi.
Carla Vitola Gonzalves.
Victor Tejada.
Daiana Martins.
Fabine Karam.
Silvia Machado dos Santos.
Roberta Raseira Caldeira.
Gisele Zanetti Senhorin.
Susi Lauz.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.amsu.2018.08.009.

References

[1] H.O. Smith, M. Berwick, C.F. Verschraegen, C. Wiggins, L. Lansing, C.Y. Muller, C.R. Qualls, Incidence and survival rates for female malignant germ cell tumors, Obstet. Gynecol. 107 (2006) 1075–1085, https://doi.org/10.1097/01.AOG.0000216004.22588.ce.

[2] H. Al Husaini, H. Soudy, A. El Din Darwish, M. Ahmed, A. Eltigani, A.L.M. Mubarak, A.A. Sabaa, W. Edesa, A.T. L-Tweigeri, I.A. Al-Badawi, Pure dysgerminoma of the ovary: a single institutional experience of 65 patients, Med. Oncol. 29 (2012) 2944–2948, https://doi.org/10.3892/mco.2016.915.

[3] T. Zhao, Y. Liu, H. Jiang, H. Zhang, Y. Lu, Management of bilateral malignant ovarian germ cell tumors: experience of a single institute, Molec. Clin. Onc. 5 (2016) 383–387, https://doi.org/10.3892/mco.2016.915.

[4] J. Meisel, K.M. Woo, N. Sudarson, J. Eng, S. Patil, E.P. Jacobsen, et al., Development of a risk stratification system to guide treatment for female germ cell tumors, Gynecol. Oncol. 138 (3) (2015) 566–572, https://doi.org/10.1016/j.ygyno.2015.06.029.

[5] W. Xu, Y. Li, Is Omentectomy Mandatory Among Early Stage (I, II) Malignant ovarian germ cell tumor patients? A retrospective study of 223 cases, Int. J. Gynecol. Canc. 27 (2017) 1373–1378, https://doi.org/10.1097/IGC.

[6] R.A. Agha, A.J. Fowler, A. Saetta, I. Barai, S. Rajmohan, D.P. Orgill, For the SCARE Group, the SCARE statement: consensus-based surgical case report guidelines, Int. J. Surg. 34 (2016) 180–186.

[7] E. Kudela, M. Nachajova, K. Biringer, P. Slavik, L. Plank, Bilateral ovarian angiosarcoma arising from the mature cystic teratomas – a case report and review of the literature, Int. J. Surg. Case Rep. 42 (2017) 90–93 https://doi.org/10.1016/j.ijscr.2017.11.064.

[8] L. Zogbi, A. Isifas, P.A. Machado, A. Neutzling, C. Juliano, Krukenberg’s tumour unilateral giant metachronous of colonic origin – case report, Int. J. Surg. Case Rep. 41 (2017) 184–187 https://doi.org/10.1016/j.ijscr.2017.10.029.

[9] A. Idleca, Y. Maazouzi, J.L. Herraitz, M.C. Medina, D. Piquer, B. Segarra, R. Del Moral, A. Serra, G. Bannós, Treatment and follow-up in an asymptomatic malignant struma ovarii: a case report, Int. J. Surg. Case Rep. 40 (2017) 113–115 https://doi.org/10.1016/j.ijscr.2017.09.005.

[10] R. Mechera, T. Menter, D. Oertli, H. Hoffmann, Large ovarian cystadenofibroma causing large bowel obstruction in a patient with Klippel–Feil syndrome—a case report, Int. J. Surg. Case Rep. 20 (2016) 17–20 https://doi.org/10.1016/j.ijscr.2015.12.046.

[11] N.M. Kamal, U. Khan, S. Mirza, K. Mazoum, F.M. Mirza, M. Jundi, Ovarian dysgerminoma with normal serum tumour markers presenting in a child with precocious puberty, J. Canc. Res. Therapeut. 11 (3) (2015) 661, https://doi.org/10.4103/0973-1482.137920.

[12] J. Li, W. Xiaohua, Current strategy for the treatment of ovarian germ cell tumors: role of extensive surgery, Curr. Treat. Options Oncol. 17 (2016) 44, https://doi.org/10.1007/s11864-016-0416-2.

[13] O. Solheim, D.M. Gershenson, C.G. Trope, E. Rokkones, C.C. Sun, H. Weedon-Fekjaer, S.D. Possa, Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978–2010), Eur. J. Canc. 50 (2014) 1942–1950 https://doi.org/10.1016/j.ejca.2014.03.288.

[14] H. Mahdi, S. Kumar, S. Seward, A. Semaan, R. Batchu, D. Lockhart, H. Tamimi, A.R. Munkarah, Prognostic impact of laterality in malignant ovarian germ cell tumors, Int. J. Gynecol. Canc. 21 (2011) 257–262, https://doi.org/10.1097/IGC.0b013e31820581e5.

[15] C. Sigismondi, P. Sosillo, G. Ferrandina, M. Candiani, R. Angioli, R. Vigano, G. Scarfone, G. Mangili, Management of bilateral malignant ovarian germ cell tumors A MITO-9 Retrospective Study, Int. J. Gynecol. Canc. 25 (2015) 203–207, https://doi.org/10.1097/IGC.0000000000000358.